Table 2.
Training Dataset (2/3 random sample)
|
Validation Dataset (1/3 random sample)
|
||||
---|---|---|---|---|---|
MACS (n= 350) | CKID (n= 546) | p-valuea | MACS (n= 177) | CKiD (n= 274) | |
Iohexol injection (mg) | 3180 [3151, 3243] | 3190 [3156, 3223] | 0.426 | 3185 [3127, 3223) | 3192 [3160, 3228] |
Fast area b (mg min/ml) | 3.2 [2.6, 3.9] | 5.7 [4.0, 8.1] | <0.001 | 3.4 [2.8, 4.1] | 5.3 [3.7, 8.2] |
Slow areac (mg min/ml) | 21.9 [18.6, 25.5] | 107.6 [73.9, 156.2] | <0.001 | 21.3 [18.7, 25.0] | 97.5 [63.8, 142.8] |
GFR0,2d (ml/min | 1.73 m2) | 125.3 [105.5, 149.0] | 45.3 [33.4, 59.2] | <0.001 | 128.3 [110.0, 150.1] | 47.7 [36.2, 63.6] |
GFR2,2e (ml/min | 1.73 m2) | 108.6 [93.8, 126.2] | 42.9 [32.0, 54.8] | <0.001 | 112.1 [96.3, 124.9] | 45.4 [34.6, 58.6] |
MACS, Multicenter Aids Cohort Study; CKiD, Chronic Kidney Disease in Children Cohort Study
Wilcoxon rank-sum test comparing MACS and CKiD in training dataset, bold indicates statistically significant (p< 0.05).
Based on plasma samples at 10 and 30 minutes after iohexol injection
Based on plasma samples at 120 and 240 for MACS and 120 and 300 for CKiD minutes after iohexol injection
(iohexol injection/ slow area) × (1.73 / BSA)
(iohexol injection/ total area) × (1.73 / BSA)